Moderna Restructuring +6.3% as FDA Momentum Builds
Can Moderna Restructuring turn an mRNA pioneer into a true multi-product biotech contender before its next major FDA test? Maik Kemper Editor in Chief The Moderna Restructuring isn’t…
Merck Protillion Collaboration Sends MRK Soaring 15%
Can the Merck Protillion Collaboration really help MRK outrun its post-Keytruda patent fears and justify Wall Street’s sudden excitement? Maik Kemper Editor in Chief This isn’t incremental —…
Johnson & Johnson IMAAVY: $24B Revenue Surge in Focus
Can Johnson & Johnson IMAAVY and a $24 billion quarter finally convince investors that JNJ deserves a higher growth multiple? Maik Kemper Editor in Chief Patients increasingly want…
Eli Lilly Acquisition $3.8B Push Opens Vaccine Growth Lane
Can Eli Lilly turn obesity cash into its next blockbuster by spending $3.83 billion on vaccines? Maik Kemper Editor in Chief The deals reflect a deliberate strategy to…
Eli Lilly Earnings +56%: Can the GLP‑1 Boom Last?
Are Eli Lilly Earnings riding a temporary GLP‑1 sugar high, or is this the start of a durable new profit cycle? Maik Kemper Editor in Chief 2026 is…
Eli Lilly Acquisition Boom: $2.3B Ajax Oncology Shock
Is the latest Eli Lilly Acquisition of Ajax Therapeutics a smart oncology pivot or a risky $2.3 billion side bet? Maik Kemper Editor in Chief Conclusion Overall, the…
Johnson & Johnson Earnings +9.9% Surge With Dividend Hike
Can Johnson & Johnson’s latest earnings surge and dividend hike still justify its premium valuation for long-term investors? Maik Kemper Editor in Chief We’ve added new products to…
Novo Nordisk AI Partnership Boom: Can It Close the Obesity Gap?
Can the Novo Nordisk AI Partnership with OpenAI turn a battered obesity champion into the next big winner of the healthcare AI boom? Maik Kemper Editor in Chief…
Eli Lilly GLP-1 Strategy Boom and Revenue Shock
Can Eli Lilly’s GLP-1 boom keep powering the stock as regulation, lawsuits and ETF concentration risks close in? Maik Kemper Editor in Chief Conclusion The Eli Lilly GLP-1…
Johnson & Johnson FDA approval ICOTYDE Boom Explained
Can Johnson & Johnson’s FDA approval of ICOTYDE really shift the psoriasis market enough to move a $575 billion healthcare giant? Maik Kemper Editor in Chief ICOTYDE delivers…